- Home
- RELY vs CNTA Comparison
RELY vs CNTA Comparison
Compare RELY & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELY | CNTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RELY | CNTA |
|---|---|---|
| Price | $16.75 | $26.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $24.13 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 263.16 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,635,147,000.00 | N/A |
| Revenue This Year | $19.99 | N/A |
| Revenue Next Year | $18.40 | N/A |
| P/E Ratio | $52.42 | ★ N/A |
| Revenue Growth | ★ 29.37 | N/A |
| 52 Week Low | $12.08 | $9.60 |
| 52 Week High | $24.63 | $30.58 |
Technical Indicators
Market Signals| Indicator | RELY | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 64.73 |
| Support Level | $15.17 | $21.93 |
| Resistance Level | $17.39 | $30.29 |
| Average True Range (ATR) | 0.76 | 1.13 |
| MACD | 0.38 | 0.29 |
| Stochastic Oscillator | 78.79 | 82.81 |
Price Performance
Historical ComparisonAbout RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.